ライフサイエンスコーパス: drug abuse

1 anxiety, motivation for change, and years of drug abuse).

2 reward system and are critically involved in drug abuse.

3 n to the opioid receptors including pain and drug abuse.

4 at have been translated to in vivo models of drug abuse.

5 lapse prevention agent for multiple types of drug abuse.

6 related to the pursuit of rewards to promote drug abuse.

7 , Patterson Trust, and National Institute on Drug Abuse.

8 identify shared environmental influences on drug abuse.

9 with increased susceptibility to alcohol and drug abuse.

10 a potential pharmacotherapeutic to decrease drug abuse.

11 rmacotherapeutic target for the treatment of drug abuse.

12 n 'gateway drug' effects in animal models of drug abuse.

13 heir potential role in the predisposition to drug abuse.

14 in, oedema and rubor of right lower limb and drug abuse.

15 nd Alcoholism, and the National Institute on Drug Abuse.

16 ditis, immunocompromising comorbidities, and drug abuse.

17 ality, such as impulsivity, risk-taking, and drug abuse.

18 such as relapse in psychiatric disorders and drug abuse.

19 otinic systems also have well-known roles in drug abuse.

20 different brain regions following hypoxia or drug abuse.

21 flammation associated with HIV infection and drug abuse.

22 search and Quality and National Institute on Drug Abuse.

23 ced behavioral changes and susceptibility to drug abuse.

24 arning and cognitive performance relevant to drug abuse.

25 has been proposed to be an endophenotype for drug abuse.

26 ar circuitry involved in reward learning and drug abuse.

27 lie the pathophysiology of schizophrenia and drug abuse.

28 on may offer a therapeutic option to address drug abuse.

29 lamine signaling has long been implicated in drug abuse.

30 rticipants with previous and current non-AAS drug abuse.

31 reward are two significant risk factors for drug abuse.

32 y is an intrinsic motivator for cessation of drug abuse.

33 ially useful tool to sustain abstinence from drug abuse.

34 s problematic impulsive behaviour, including drug abuse.

35 atment for HIV, hepatitis C virus (HCV), and drug abuse.

36 ogical tools for behavioural intervention in drug abuse.

37 interventions are highly required to combat drug abuse.

38 rimary Funding Source: National Institute on Drug Abuse.

39 t R01-DA15612 from the National Institute on Drug Abuse.

40 of the cerebellum in psychiatric disease and drug abuse.

41 t role in the development and persistence of drug abuse.

42 standard method for the detection of chronic drug abuse.

43 Prevalences of 12-month and lifetime drug abuse (1.4% and 7.7%, respectively) exceeded rates

44 alcohol abuse (10.1% vs 3.8%, P < .001) and drug abuse (11.4% vs 6.9%, P < .01) compared with those

45 betes (26%), congestive heart failure (23%), drug abuse (20%), and hypertension (17%).

46 DSM-IV drug abuse or dependence; (2) DSM-IV drug abuse; (3) DSM-IV drug dependence; and (4) emerging

47 septicemia (14.0% vs. 7.3%; p < 0.001), and drug abuse (4.3% vs. 0.7%; p < 0.001) compared with medi

48 r septicemia (15.6% vs. 5.2%; p < 0.001) and drug abuse (7.3% vs. 0.9%; p < 0.001) compared with non-

49 rders (alcohol abuse, 96.5 [0.67]; P < .001; drug abuse, 97.6 [0.64]; P = .02), and specific phobia (

50 tation was the only independent predictor of drug abuse after transplantation (P=0.017).

51 s to ART initiation, including non-injection drug abuse, alcohol abuse, and mental illness.

52 at onset </=21) subjects had higher risks of drug abuse, alcohol abuse, rapid cycling, and suicide at

53 sources of parent-offspring resemblance for drug abuse, alcohol use disorders, and criminal behavior

54 registries, the authors identified rates of drug abuse, alcohol use disorders, and criminal behavior

55 For drug abuse, alcohol use disorders, and criminal behavior

56 ies to record, diagnose, or treat underlying drug abuse among patients presenting with IDU-related in

57 recent data on the prevalence of additional drug abuse among those misusing prescription opioids.

58 ming and nursing, depression and stress, and drug abuse, among others.

59 The underlying molecular mechanisms of drug abuse and addiction behaviors are poorly understood

60 rol; and misconceptions and prejudices about drug abuse and addiction contribute to this educational

61 ive decision-making is a defining feature of drug abuse and addiction, we have yet to ascertain how c

62 c festival, is notorious for the problems of drug abuse and addiction.

63 can facilitate more effective treatments of drug abuse and addiction.

64 ten serve as animal vulnerability models for drug abuse and addiction.

65 pigenetic landscape likely underlies chronic drug abuse and addiction.

66 Distances ranged from 0.070 (between drug abuse and alcohol dependence) to 1.032 (between dru

67 Externalizing disorders-drug abuse and alcohol use disorders-demonstrated the th

68 xual behavior, aggression, circadian rhythm, drug abuse and anxiety implicate 5-HT(3A) receptors in t

69 sed to study a link between vulnerability to drug abuse and anxiety-like reactivity.

70 ous neuropsychiatric disorders, particularly drug abuse and attention-deficit/hyperactivity disorder

71 Twelve-month and lifetime prevalence of drug abuse and dependence and the associated correlates,

72 or more symptoms that operationalize DSM-IV drug abuse and dependence criteria.

73 To present detailed information on drug abuse and dependence prevalence, correlates, and co

74 o be associated with alcoholism and multiple drug abuse and dependence.

75 unwanted side effects and the potential for drug abuse and diversion.

76 se and alcohol dependence) to 1.032 (between drug abuse and dysthymia).

77 ave implications for our etiologic models of drug abuse and especially for contingency management pro

78 National Institute on Drug Abuse and Gilead Sciences.

79 ystem to investigate the association between drug abuse and HIV infection in HIV-PAH development.

80 play a pathophysiologic role in anxiety and drug abuse and is a potential therapeutic target in thes

81 g given a worldwide epidemic of prescription drug abuse and its devastating socioeconomic impacts on

82 ave an important role in the early stages of drug abuse and may drive the increased drug seeking and

83 of clinical evidence on comorbidity between drug abuse and mood disorders, we used this model to inv

84 National Institute on Drug Abuse and National Institute of Allergy and Infecti

85 design of D3R-selective agents for treating drug abuse and other neuropsychiatric indications.

86 e a major risk factor for the development of drug abuse and other unsafe behaviors.

87 Those with concurrent drug abuse and recurrent major depressive disorder were

88 An important factor in the risk of drug abuse and relapse is stress.

89 to mediate the complex relationship between drug abuse and social bonding.

90 etion of NOP receptors confers resilience to drug abuse and support a role for NOP receptor antagonis

91 National Institute on Drug Abuse and the Lifespan/Tufts/Brown Center for AIDS

92 The National Institute on Drug Abuse and the National Institute of Mental Health f

93 National Institute on Drug Abuse and the Robert Wood Johnson Foundation.

94 opioid receptor family, is involved in pain, drug abuse, and a number of other CNS processes.

95 physiology of depression, anxiety disorders, drug abuse, and alcoholism.

96 nt symptoms, and (3) early-onset recurrence, drug abuse, and crime.

97 rons has been implicated in reward learning, drug abuse, and motivation.

98 tute of Mental Health, National Institute on Drug Abuse, and National Center for Complementary and In

99 ociated comorbidities, such as dyslipidemia, drug abuse, and opportunistic infections; and lifestyle

100 te the design of novel agents to treat pain, drug abuse, and other central nervous system disorders.

101 nsion, liver disease, renal disease, illicit drug abuse, and poor performance status, but lower preva

102 Cycles of incarceration, drug abuse, and poverty undermine ongoing public health

103 rvices Administration, National Institute on Drug Abuse, and Robert Wood Johnson Foundation.

104 men had a higher prevalence of dyslipidemia, drug abuse, and smoking.

105 ates in memory for spatial tasks, relapse to drug abuse, and temporal lobe seizures.

106 H Pain Consortium, the National Institute on Drug Abuse, and the National Institute of Neurological D

107 tors for repeat IE were older age, male sex, drug abuse, and valvular replacement after an initial ep

108 In an animal model for vulnerability to drug abuse, animals that exhibit greater motor activity

109 mGlu7 function has been linked to autism, drug abuse, anxiety, and depression.

110 Similarly, those with prior drug abuse are more likely to continue drug use after tr

111 nesses, and the role of life experiences and drug abuse as causative agents in the onset of psychoses

112 ons in ERK/MAPK activity are associated with drug abuse, as well as neuropsychiatric and movement dis

113 iminished with age and with alcohol or other drug abuse, as well as reduced WM FA in the right OMPFC.

114 Recent advances in the adolescent drug abuse assessment field continue to inform clinical

115 se findings suggest an avenue for modulating drug abuse-associated changes in synaptic plasticity via

116 es of this signaling on behaviors related to drug abuse, attention, food intake, and affect.

117 titute of Criminology, National Institute on Drug Abuse, Australian Government Department of Health,

118 Charitable Foundation, National Institute on Drug Abuse, Australian National Health & Medical Researc

119 Drug abuse before transplantation was the only independe

120 of food intake increases the acquisition of drug abuse behavior and enhances the reinforcing efficac

121 MCH also modulates sleep, drug abuse behavior, and mood, and MCH receptor antagoni

122 in multiple psychiatric disorders, including drug abuse, behavioral addictions, and eating disorders

123 factors (multiple sex partners, intravenous drug abuse, blood transfusion recipients) and chronic th

124 with mortality rates similar to suicide and drug abuse, but less than expected in the general popula

125 rivation neighborhood increased the risk for drug abuse by 2%.

126 d role in the development and maintenance of drug abuse by influencing neuronal and synaptic function

127 Drug abuse by people with severe mental disorder is a si

128 nvironmental risk factors in the etiology of drug abuse by twin sibling modeling.

129 The authors predicted concordance for drug abuse by years of co-residence until the older sibl

130 animals that were trained to self-administer drugs abused by humans.

131 y is indeed a strong intrinsic motivator for drug abuse cessation.

132 the present work, we applied our established drug-abuse chemogenomics-knowledgebase systems pharmacol

133 US National Institute on Drug Abuse, Columbia University Mailman School of Public

134 ortion of the shared environmental effect on drug abuse comes from community-wide rather than househo

135 -administer opioids, and previous history of drug abuse comorbid with chronic pain promotes higher ra

136 However, the precise mechanisms by which drug abuse compromises the host immune defense to pulmon

137 Drug abuse continues to be a major problem facing our so

138 Chronic drug abuse, craving, and relapse are thought to be linke

139 crime in not-lived-with parents and by AUD, drug abuse, crime, and premature death in stepparents.

140 Prior research suggests that drug abuse (DA) is strongly influenced by both genetic a

141 Drug abuse (DA) strongly runs in families.

142 h-densities of alcohol use disorder (AUD) or drug abuse (DA).

143 of PD and to clarify its effects on risk of drug abuse (DA).

144 A known to play a role in neuroadaptation to drug abuse, decreased luciferase expression when compare

145 RIMARY FUNDING SOURCE: National Institute on Drug Abuse, Department of Veterans Affairs, and National

146 dence; alcohol abuse/dependence; and illicit drug abuse/dependence.

147 ntion deficit hyperactivity disorder (ADHD), drug abuse, depression, and Parkinson's disease (PD).

148 Relapsing to drug abuse despite periods of abstinence and sincere att

149 ls with no comorbid psychiatric, medical, or drug abuse disorders were scanned following 2 weeks of o

150 The outcome of opioid misuse was defined as drug abuse, drug misuse, aberrant drug-related behavior,

151 mothers had a greater reduction in risk for drug abuse during pregnancy (odds ratio=0.40, 95% CI=0.3

152 d within-person analyses of registration for drug abuse during pregnancy among Swedish women born bet

153 Because the drug abuse epidemic and the HIV-1 epidemic are closely i

154 ntagonists are effective in animal models of drug abuse, especially in models of relapse.

155 Drug abuse, especially with designer drugs, continues to

156 Drug abuse exacerbates HAND, but the mechanism(s) by whi

157 education and without a cohabiting, actively drug-abusing father.

158 elieved to contribute to multiple aspects of drug abuse, from preexisting vulnerability in at-risk in

159 BD with vs without lifetime alcohol or other drug abuse had significantly decreased FA in the left un

160 Since 1997 the US National Institute on Drug Abuse has advocated a brain disease model of addict

161 to E.J.C.) from the US National Institute on Drug Abuse has been added to the Acknowledgements in the

162 During the last few years, drug abuse has risen to the point that almost 20 million

163 reated pain and the epidemic of prescription drug abuse have coincided, creating a need for medical a

164 ication in macrophages and indicate that the drug abuse-heightened levels of central nervous system d

165 Its modulation by drug abuse, however, has received very little attention.

166 DLS is known to be disrupted after chronic drug abuse; however, it remains unclear what neural sign

167 Learning is a critical aspect of drug abuse; however, it remains unclear whether drug-ass

168 eadmission for endocarditis, septicemia, and drug abuse, IDU-IE presents a serious challenge to curre

169 icy announced its plan to fight prescription drug abuse in 2011 and unveiled the Risk Evaluation and

170 older sibling turned 21 and risk for future drug abuse in adolescents living with parental figures a

171 indings extend our understanding of risk for drug abuse in individuals with poor inhibitory control a

172 model predicted substantial heritability for drug abuse in males (55%) and females (73%), with enviro

173 was examined individually, hazard rates for drug abuse in offspring of parents with drug abuse were

174 The estimated odds ratio for drug abuse in pregnancy-discordant monozygotic twins was

175 gonist is the most common strategy to manage drug abuse in pregnant women.

176 One approach to decrease drug abuse in sports would be to accept that there is a

177 Risk for drug abuse in women is substantially reduced during preg

178 ical reactions to stress, anxiety, mood, and drug abuse, in addition to feeding behaviors.

179 erization of drug-related decision making in drug abuse, including effects of psychological and pharm

180 mines, synthetic marijuana, and prescription drug abuse, including several categorized and continuous

181 , the probability of sibling concordance for drug abuse increased 2%-5%.

182 Prevalence of drug abuse increased among younger birth cohorts (4.2%,

183 n of candidate antiviral therapies targeting drug-abusing individuals.

184 Moreover, because enhanced D1R signaling in drug abuse induces changes in spine density in striatum,

185 optimization of behavioral interventions and drug abuse intervention.

186 y was conducted at the National Institute on Drug Abuse Intramural Research Program outpatient magnet

187 Drug abuse is a global problem, requiring an interdiscip

188 Drug abuse is a multifaceted disorder that involves mala

189 Drug abuse is a worldwide health concern in which addict

190 n-individual analyses indicate that risk for drug abuse is also substantially reduced in the postpart

191 Drug abuse is an etiologically complex syndrome strongly

192 IGNIFICANCE STATEMENT The pandemic of opioid drug abuse is associated with many socioeconomic burdens

193 ective registry data, the authors found that drug abuse is highly heritable.

194 Adolescent drug abuse is hypothesized to increase the risk of drug

195 e over activity in this pathway, its role in drug abuse is less defined.

196 Drug abuse is often initiated as a maladaptive mechanism

197 orders (HAND) caused by HIV-1 virotoxins and drug abuse is the lack of understanding the underlying m

198 Intravenous drug abuse (IVDA) is a known risk factor for endogenous

199 Risk factors include intravenous drug abuse (IVDA), diabetes, indwelling catheters, and i

200 oons using a standard paradigm for assessing drug abuse liability; nor was any place preference found

201 euroimmune mechanisms that may contribute to drug-abuse liability, exploring evidence from opioids, a

202 re an alternative reliable method to confirm drug abuse may be required.

203 Increases in stimulant drug abuse may increase the rate of hospital admissions

204 analogues with higher potency and utility as drug abuse medications.

205 ral and psychiatric vulnerabilities, such as drug abuse, mood disorders, and schizophrenia.

206 hite), 52 resulting from suicide (n = 31) or drug abuse (n = 21) and 64 probably or likely attributab

207 of Mental Health, the National Institute on Drug Abuse, NARSAD (Early Career Award), and the William

208 d Infectious Diseases, National Institute on Drug Abuse, National Institute of Mental Health, and Mas

209 d Infectious Diseases, National Institute on Drug Abuse, National Institute of Mental Health, and the

210 National Institute on Drug Abuse, National Institutes of Health, and Departmen

211 National Institute on Drug Abuse, National Institutes of Health.

212 derstanding their impact on vulnerability to drug abuse, neuropsychiatric diseases with differential

213 The National Institute on Drug Abuse (NIDA) is designated as the sole legal produc

214 d as priorities by the National Institute on Drug Abuse (NIDA).

215 United States National Institute of Drug Abuse (NIDA).

216 social problems such as alcohol abuse, other drug abuse, noncompliance, schizophrenia, and depression

217 ustice programs have shown such promise with drug-abusing offenders.

218 ve episode, alcohol abuse or dependence, and drug abuse or dependence (adjusted relative risk, 2.7; 9

219 ma only) was associated with excess risk for drug abuse or dependence (adjusted relative risk, 4.9; 9

220 15.12), and were less likely to have current drug abuse or dependence (OR, 0.29; 95% CI, 0.90 to 0.92

221 lsive disorder), substance use disorder (ie, drug abuse or dependence and alcohol abuse or dependence

222 lso had a greater adjusted relative risk for drug abuse or dependence compared with subjects exposed

223 3-5 chronic kidney disease (CKD), alcohol or drug abuse or dependence diagnosis, and anemia.

224 choactive substance use disorder (alcohol or drug abuse or dependence) has been consistently reported

225 abuse or dependence, and 6.7% vs. 17.6% for drug abuse or dependence.

226 ncluding being without history of alcohol or drug abuse or dependence.

227 e use disorders, such as alcohol and illicit drug abuse or dependence.

228 ow-up assessments, newly incident (1) DSM-IV drug abuse or dependence; (2) DSM-IV drug abuse; (3) DSM

229 d individuals diagnosed (without intravenous drug abuse or hepatitis C infection) (n = 3205), and a b

230 tients on methadone maintenance therapy at a drug abuse outpatient center.

231 rapeutic interventions for disorders such as drug abuse, overeating, or pathological gambling.

232 Despite the likely role of GLU release in drug abuse pathology, there is no information that links

233 ease, anesthesiologists must learn to detect drug abusing patients and avoid known interactions.

234 Institutes of Health, National Institute on Drug Abuse, Penn Centre for AIDS Research, and Penn Ment

235 idered a potential target for development of drug abuse pharmacotherapies, especially for alcoholism,

236 Consequently, although drug abuse policy should focus on limiting supplies of p

237 ease and meningitis in the immunocompromised drug abuse population.

238 phisms (R6G;E42G) within the HTR2B gene in a drug-abusing population, we assessed whether these polym

239 als (RCTs) of universal, middle school-based drug abuse prevention curricula are the most useful indi

240 s hindered the effectiveness of school-based drug abuse prevention curricula overall.

241 The alternative approach of using drug abuse prevention resources on treatment and demand-

242 derstanding of Captagon addiction and future drug abuse prevention.

243 n: childhood sexual abuse, conduct disorder, drug abuse, prior history of major depression, and dista

244 edicine, and psychiatry have higher rates of drug abuse, probably related to the high-risk environmen

245 ffspring was significantly predicted by AUD, drug abuse, psychiatric illness, and crime in not-lived-

246 astasis, rheumatologic diseases, alcohol and drug abuse, psychoses, and depression compared to the ge

247 Patients had no history of drug abuse, psychosis, dementia/neurodegenerative diseas

248 Drug abuse recorded in medical, legal, or pharmacy regis

249 MAIN OUTCOME MEASURES: Drug abuse recorded in medical, legal, or pharmacy regis

250 portant difference between overeating versus drug abuse refers to the sensory stimulation of oral rec

251 a profile of interest for the development of drug abuse relapse prevention therapies or antidepressan

252 treating substance dependence and preventing drug abuse relapse.

253 romote the development of certain aspects of drug abuse-related behavior.

254 Cocaine is the leading cause for drug-abuse-related visits to emergency departments, most

255 Effective medications for drug abuse remain a largely unmet goal in biomedical sci

256 of HIV-associated neurological disorder and drug abuse, remains essentially unknown.

257 vel emerging aquatic models in translational drug abuse research and small molecule screening.

258 NPS receptors may be an important target for drug abuse research and treatment and that CRF(1) mediat

259 ditis, typically associated with intravenous drug abuse, rheumatic heart disease, prosthetic heart va

260 ngency management programs seeking to reduce drug abuse risk.

261 In the self-administration model of drug abuse, Ro 61-8048 reduced the rewarding effects of

262 Eye-Opener/Amnesia/C[K]ut Down on Drinking), Drug Abuse Severity Test, and the 12-Item Short-Form Hea

263 system drug class is highly associated with drug abuse terms such as dependence, substance abuse, an

264 l flow assays (LFAs) are an ideal choice for drug abuse testing favored by their practicability, port

265 at there may be more complex consequences of drug abuse than current theories have explored, especial

266 ical siblings who have no history of chronic drug abuse; these findings support the idea of an underl

267 ocesses in vivo, including those relevant to drug abuse, thus providing a potential mechanistic basis

268 disorders including depression, anxiety, and drug abuse, thus the development of novel KOR antagonist

269 Although it is more common for drug abuse to progress from tobacco to cannabis, in many

270 ltisite study, conducted within the National Drug Abuse Treatment Clinical Trials Network, comparing

271 Aggressive drug abuse treatment immediately after a first psychiatr

272 A promising strategy for drug abuse treatment is to accelerate the drug metabolis

273 selectivity and for the development of novel drug abuse treatments.

274 examine the potential of these compounds as drug-abuse treatments, we extended the previous assessme

275 One approach to treating drug abuse uses antidrug antibodies to immunize subjects

276 In animals and humans, vulnerability to drug abuse varies among individuals.

277 US National Institute on Drug Abuse; Veterans Administration.

278 may contribute to individual differences in drug abuse vulnerability and that these are likely attri

279 ore novel neurobiological systems underlying drug abuse vulnerability.

280 he known protective effects of enrichment on drug abuse vulnerability.

281 (CREM) in mediating impulsivity relevant to drug abuse vulnerability.

282 delay discounting procedure is predictive of drug abuse vulnerability; however, the shared underlying

283 Drug abuse was assessed from medical, criminal, and phar

284 Drug abuse was defined using public medical, legal, or p

285 e negative association between pregnancy and drug abuse was moderately stronger in cousins (odds rati

286 Risk for drug abuse was predicted both by family socioeconomic st

287 idity, depressive symptoms, and prescription drug abuse were also independently associated with frail

288 ellitus, obesity, smoking, dyslipidemia, and drug abuse were analyzed in these patients.

289 When age, socioeconomic status, and drug abuse were controlled for, hazard ratios declined o

290 disorder, hearing difficulty, or history of drug abuse were excluded.

291 for drug abuse in offspring of parents with drug abuse were highest for mothers (2.80, 95% CI=2.23-3

292 In the population, rates of drug abuse were lower during pregnancy (unadjusted odds

293 eficiency anemia, obesity, alcohol abuse, or drug abuse) were associated with higher odds for hospita

294 hysicians should be highly inquisitive of IV drug abuse when presented with cases of TMA.

295 nsequences, such as depression and increased drug abuse, which, in turn, contribute to HIV transmissi

296 Within individuals, the odds ratio for drug abuse while pregnant compared with an equivalent pr

297 disorder and aggregates, possibly along with drug abuse, within families.

298 neurotensin receptor ligand that may curtail drug abuse without the side effects induced by G protein

299 d illicit drug use (3.3% vs. 0.6% males with drug abuse, Z=2.04, p<0.05; 2.6% vs. 0.1% females with d

300 , Z=2.04, p<0.05; 2.6% vs. 0.1% females with drug abuse, Z=5.36, p<0.001; 3.4% vs. 1.1% males with dr